Opportunities and Challenges: Early Development of Immuno-Oncology Therapies
Date and Time
Thursday May 28, 2020
1:00 PM - 1:45 PM EDT
May 28
1:00 - 1:45 p.m.
Location
Webinar
Fees/Admission
Website
Contact Information
Hosted by LaunchBio
Opportunities and Challenges: Early D...
Description
Evasion or inhibition of immune surveillance has been shown to be a major mechanism limiting the effectiveness of traditional therapies against tumor cells. However, recent breakthroughs in immuno-oncology research have established that harnessing of the immune system is a powerful way to combat cancer. This panel discussion will address key considerations and challenges in immuno-oncology drug development from discovery research to nonclinical safety assessment.
In this webinar you will learn about:
In this webinar you will learn about:
- Pros and cons of different animal models based on mechanism of action
- Identifying the best study design and endpoints based on target
- Key considerations when developing a pre-clinical safety assessment strategy to support the first in human clinical trial
Speakers:
- Pete Gaskin, PhD, ERT, MTOPRA, SENIOR DIRECTOR, Charles River Laboratories
- Stephen Festin, PhD, Director of Scientific & Commercial Dev., Charles River Laboratories
- Joseph A. Francisco, PhD, SR Director, Scientific Advisory Services, Charles River Laboratories
- Patrick Fadden, PhD, Research Director, Charles River Laboratories
